IL33 and metabolic disease: Since the above results show that IL-33 ameliorated dietary-derived metabolic disorders in visceral adipose tissue via activation of ILC2, we next administered ILCs collected from the bone marrow of CD45.1 mice transvenously to ST2KO mice (Supplemental Figure 9) (Figure 5A).